Accelerating Lead Generation: Emerging technologies and strategies

This report provides an in-depth examination of state-of-the-art technologies for lead generation.

The Top 10 Biosimilar Players: Positioning, performance and SWOT analyses

Biologics continue to outperform the global pharma market, driven by premium priced therapies for conditions that cannot be managed by conventional drugs. The rapid penetration of novel biologics and the gradual expiry of their patents will create significant market opportunities for biosimilars developers through to 2016.

Managing cost containment and safeguarding productivity

For several years, drug developers have been under intense pressure to introduce new products in an environment of escalating R&D costs, blockbuster patent expiration and resulting generic competition, increasingly complex science, heightened regulatory scrutiny, and other pressures. Now, however, the global economic meltdown has added new imperatives for drug makers to cut costs.

Maximizing opportunities towards achieving clinical success

For the last few years the biggest pharma companies have started to bring new technologies for drug safety prediction into the discovery phases of research. This report will describe these technologies, their place in the drug discovery and development paradigm and their value for improving drug safety.

Forecast Analysis

The high cost and utilization of biologic drugs, coupled to the growing need to curb pharmaceutical expenditure, provides considerable momentum to the emerging biosimilars market. With a biosimilar approval pathway in place in Europe and Japan, and imminently in the US, Datamonitor expects payer pressure to drive biosimilar uptake, particularly in Germany, the US, and the UK.

Physician perception of biologics in autoimmune disease - Targeted detailing is the key to success

Factors influencing a prescribing decision can diverge from clinical facts. In the highly competitive autoimmune area, misconceptions and physician habits can result in loss of sales. Targeted detailing of specialist physicians, differentiating by indications is the key to success. Datamonitor has surveyed gastroenterologists, rheumatologists and dermatologists on attribute and brand perceptions

New Approaches to Pharma R&D: Evolving strategies to rejuvenate R&D efficiency

With industry consolidation, the economic downturn, and an increasing threat from generics, pharma companies are coming under greater pressure to fill their pipelines with innovative drugs. However, despite the costs and risks involved in drug development, the pharma industry is finding new ways to streamline the R&D process in an effort to increase efficiency and output.

Forecast Analysis

The high cost and utilization of biologic drugs, coupled to the growing need to curb pharmaceutical expenditure, provides considerable momentum to the emerging biosimilars market. With a biosimilar approval pathway in place in Europe and Japan, and imminently in the US, Datamonitor expects payer pressure to drive biosimilar uptake, particularly in Germany, the US, and the UK.

Pricing and Reimbursement in Key Asia Pacific Markets

With the Asia-Pacific markets growing rapidly, they are becoming increasingly attractive for Pharma to enter. However, a number of key P&R developments and reforms are set to change the healthcare environment in the next few years, as healthcare is made more accessible to the poor and elderly.

Key Trends in Offshoring Pharmaceutical R&D: Company strategies, emerging markets and impact on ROI

‘Key Trends in Offshoring Pharmaceutical R&D' is a report published by Business Insights that evaluates the offshore R&D strategies that can reduce development times and improve productivity, with analysis of a variety of strategic partnerships, academic collaborations, and outsourcing opportunities.

Gastric Cancer - Targeted therapies compete for first-to-market status

Gastric cancer incidence in 2009 is forecast to be 197,000 in the seven major pharmaceutical markets (US, Japan, Germany, France, Italy, Spain, and UK). Although, the global incidence has decreased in recent years, mortality remains high, particularly in the US and Europe. Therefore, predictably a high unmet need remains for effective therapies to improve mortality.

Pharmaceuticals: Global Industry Almanac

Datamonitor's Pharmaceuticals: Extended Global Industry Guide is an essential resource for top-level data and analysis covering the Pharmaceuticals industry. It includes detailed data on market size and segmentation, textual analysis of the key trends and competitive landscape, and profiles of the leading companies. This incisive report provides expert analysis on a global, regional and country basis.

Schizophrenia - Second generation depots protect market value

Schizophrenia is a chronic and severe mental health disorder affecting around 4.6 million schizophrenia sufferers across the seven major markets. Currently led by oral branded atypical antipsychotics, the schizophrenia market will undergo some big changes over the period 2008/2017. Prospective players can expect to face stiff competition from generic versions of all currently branded drugs.

Commercial dynamics and outlook of the neurology, pain and psychiatry market sectors

The market for CNS drugs across the 7MM was worth a substantial $95.5 billion, accounting for a 21.4% share of the total pharmaceutical market value in 2007. Despite stalling R&D productivity and the genericization of the majority of leading CNS blockbuster brands, the market continues to offer a wealth of lucrative opportunities for all types of drug manufacturer.

Pricing and Reimbursement in The United Arab Emirates

The healthcare sector in the emirates of Abu Dhabi and Dubai is undergoing drastic changes as a result of the structural and financing reforms that will impact all major actors in the healthcare sector.

Vaccine administration technologies - Beyond needles

Novel vaccine administration technologies have the potential to improve vaccine developers' commercial competitiveness and to increase vaccination safety and convenience. This report assesses key strategies, technologies and products for novel dermal and mucosal vaccine administration. It also provides an overview of opportunities and challenges for the sector and a future outlook.

Pharma 2020: The vision

Which path will you take?

Demand for effective medicines is rising, as the population ages, new medical needs emerge and the disease burden of the developing world increasingly resembles that of the developed world. The E7 countries - Brazil, China, India, Indonesia, Mexico, Russia and Turkey - are also becoming much more prosperous, with real gross domestic product (GDP) projected to triple over the next 13 years. By 2020, the E7 could account for as much as one-fifth of global sales.

Donwnload free 52 pages report at our Download Section

Virtual R&D - Which path will you take?

Pharma is at a pivotal point in  its evolution. Social, demographic  and economic milieu in which the  industry operates is undergoing huge  changes. These challenges have  been compounded by the dearth of  good new compounds in its pipeline.

Donwnload free 24 pages report at our Download Section